IBIO NASDAQ
iBio, Inc.
1W: -5.0%
1M: -13.7%
3M: -30.2%
YTD: -44.1%
1Y: +37.2%
3Y: -80.5%
5Y: -99.8%
$1.12
+0.01 (+1.35%)
Weekly Expected Move ±6.9%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
21 relationships20
As Filer
counterparties named
1
As Counterparty
mentioned by others
6
Rel. Types
2021-05-04
Earliest Filing
2026-02-27
Latest Filing
partner: 10
investor: 3
target: 3
customer: 2
acquirer: 1
supplier: 1
Counterparties (Filed by IBIO)
20 relationshipsCompanies named in IBIO's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Jefferies LLC | JEF | partner | Entered into an Open Market Sale Agreement to act as agent for the sale of iBio, Inc. common stock. | 2026-02-27 | View |
| Chardan Capital Markets, LLC | — | partner | Previous agent under a terminated At Market Issuance Sales Agreement. | 2026-02-27 | View |
| Craig-Hallum Capital Group LLC | — | partner | Previous agent under a terminated At Market Issuance Sales Agreement. | 2026-02-27 | View |
| AstralBio, Inc. | — | partner | Entered into an exclusive license agreement to license patents and know-how for developing and commercializing activin E | 2025-04-22 | View |
| AstralBio, Inc. | — | partner | Entered into an exclusive license agreement to license patents and know-how for GDF8 (myostatin) products. | 2025-01-02 | View |
| Chardan Capital Markets, LLC | — | partner | Sales Agent for At Market Issuance Sales Agreement | 2024-07-03 | View |
| Craig-Hallum Capital Group LLC | — | partner | Sales Agent for At Market Issuance Sales Agreement | 2024-07-03 | View |
| The Board of Regents of the Texas A&M University System | — | customer | Counterparty in the sale of property assets including buildings and equipment. | 2024-05-20 | View |
| Otsuka Pharmaceutical Co., Ltd. | — | acquirer | Acquired PD-1 agonist assets from iBio, Inc. for $1M plus potential contingent payments. | 2024-02-26 | View |
| RubrYc Therapeutics, Inc. | — | supplier | Sold substantially all assets including AI drug discovery platform and immuno-oncology candidates to iBio, Inc. | 2024-02-26 | View |
| Majestic Realty Co. | — | customer | Purchaser of iBio CDMO's cGMP biologics manufacturing facility | 2023-09-21 | View |
| Lincoln Park Capital Fund, LLC | — | investor | Entered into a purchase agreement and registration rights agreement to potentially purchase up to $10 million of iBio, I | 2023-08-04 | View |
| H.C. Wainwright & Co., LLC | — | investor | Sole book-running manager and underwriter for the public offering of common stock and warrants. | 2022-12-08 | View |
| RubrYc Therapeutics, Inc. | — | target | Acquired substantially all assets including AI drug discovery platform and immuno-oncology candidates in exchange for st | 2022-09-21 | View |
| Eastern Capital Limited | ELOG | investor | Parent company of College Station Investors LLC and Bryan Capital Investors LLC, the sellers in the transaction. | 2021-11-04 | View |
| College Station Investors LLC | — | target | Seller of the manufacturing facility and equity interests in iBio CDMO LLC. | 2021-11-04 | View |
| Bryan Capital Investors LLC | — | target | Seller of the manufacturing facility and equity interests in iBio CDMO LLC. | 2021-11-04 | View |
| Texas A&M University System | — | partner | Landowner of the facility property and original landlord under the Ground Lease Agreement. | 2021-11-04 | View |
| RubrYc Therapeutics, Inc. | — | partner | Partnered with iBio, Inc. for an exclusive license to RTX-003 antibodies, a collaboration on AI-based antibody discovery | 2021-08-27 | View |
| Fraunhofer USA, Inc. | — | partner | Settlement agreement and mutual release regarding plant-based technology ownership and licensing | 2021-05-04 | View |
Mentioned As Counterparty
1 mentionsOther companies that named IBIO in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-14 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-28 | Earnings Release; Exhibits | View | |
| 2026-08-04 | Officer/Director Change; Other Events; Exhibits | View | |
| 2026-07-17 | Other Events; Exhibits | View | |
| 2026-07-01 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-12 | Earnings Release; Exhibits | View | |
| 2026-05-08 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-04-17 | Other Events | View | |
| 2026-04-08 | Regulation FD; Other Events; Exhibits | View | |
| 2026-03-09 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2026-02-27 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Financial St | Agreement | View |
| 2026-02-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-12 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-11-21 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-11-17 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-04 | Other Events | View | |
| 2025-10-30 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-21 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR